Cargando…
Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
Subcutaneous pegcetacoplan (EMPAVELI(®) in the USA and ASPAVELI(®) in the EU) is the first complement component 3 (C3) inhibitor approved for the treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH) in the USA, and in adults with PNH who are anaemic after ≥ 3 months of treatment with...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234880/ https://www.ncbi.nlm.nih.gov/pubmed/36459381 http://dx.doi.org/10.1007/s40265-022-01809-w |